Search results
Results From The WOW.Com Content Network
Alcon offices in Johns Creek, Georgia. Alcon Inc. ( German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It has a paper headquarters in Geneva, Switzerland but its operational headquarters are in Fort Worth, Texas, United States, where it employs about 4,500 people. [2]
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
The total cost to Novartis for the 77% stake in Alcon was $38.7 billion ($168 per share). In the deal's first phase, Novartis acquired a 25% stake in Alcon from Nestlé for $10.4 billion in July 2008.
LEO – LEO Pharma. LifeScan – LifeScan. Lilly – Eli Lilly and Company Ltd. Lundbeck – Lundbeck Ltd. Martindale Pharma – Martindale Pharmaceuticals - Ltd (Now Ethypharm UK) Mölnlycke – Mölnlycke Health Care Ltd. Mayne – Mayne Pharma plc. McNeil – McNeil Laboratories Ltd. Meda – Meda Pharmaceuticals Ltd.
Alcon relocated its headquarters to Geneva in 2018, citing an opportunity to “increase Alcon’s global scale and reach to better serve customers.” The company employs a total of 25,000 people.
www .actavis .com. Actavis Generics [1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products.
For premium support please call: 800-290-4726 more ways to reach us
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.